Collegium Pharmaceutical, Inc. Net Income (Loss) Attributable to Parent, Diluted
Collegium Pharmaceutical, Inc. (COLL) reported Net Income (Loss) Attributable to Parent, Diluted of -$15.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2026-06-30 was -$15.05M, a 211.78% decline year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2026-03-31 was $15.99M, a 561.69% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-12-31 was $18.45M, a 31.39% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-09-30 was $33.07M, a 207.59% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for fiscal 2025 was $68.88M, a 8.23% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for fiscal 2024 was $75.05M, a 38.87% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for fiscal 2023 was $54.04M.
- Collegium Pharmaceutical, Inc. net income (loss) attributable to parent, diluted for fiscal 2022 was -$25.00M, a 132.81% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.05M 10-Q · filed 2026-08-06 | -$555.00K 10-Q · filed 2026-08-06 | $19.39M derived: sum of 3 quarters · filed 2026-08-06 | $52.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.99M 10-Q · filed 2026-05-07 | $34.44M derived: sum of 2 quarters · filed 2026-05-07 | $67.51M derived: sum of 3 quarters · filed 2026-05-07 | $80.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $18.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $51.52M derived: sum of 2 quarters · filed 2026-02-26 | $64.98M derived: sum of 3 quarters · filed 2026-08-06 | $68.88M 10-K · filed 2026-02-26 |
| 2025-09-30 | $33.07M 10-Q · filed 2025-11-06 | $46.53M derived: sum of 2 quarters · filed 2026-08-06 | $50.43M 10-Q · filed 2025-11-06 | $62.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.46M 10-Q · filed 2026-08-06 | $17.36M 10-Q · filed 2026-08-06 | $29.92M derived: sum of 3 quarters · filed 2026-08-06 | $40.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.42M 10-Q · filed 2026-05-07 | $16.46M derived: sum of 2 quarters · filed 2026-05-07 | $27.21M derived: sum of 3 quarters · filed 2026-05-07 | $48.29M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $14.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.79M derived: sum of 2 quarters · filed 2026-02-26 | $45.88M derived: sum of 3 quarters · filed 2026-02-26 | $75.05M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.75M 10-Q · filed 2025-11-06 | $31.83M derived: sum of 2 quarters · filed 2025-11-06 | $61.01M 10-Q · filed 2025-11-06 | $99.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $21.08M 10-Q · filed 2025-08-07 | $50.26M 10-Q · filed 2025-08-07 | $88.25M derived: sum of 3 quarters · filed 2026-02-26 | $110.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $29.34M 10-Q · filed 2025-05-08 | $67.16M derived: sum of 2 quarters · filed 2026-02-26 | $89.44M derived: sum of 3 quarters · filed 2026-02-26 | $104.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $37.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $60.11M derived: sum of 2 quarters · filed 2026-02-26 | $74.79M derived: sum of 3 quarters · filed 2026-02-26 | $54.04M 10-K · filed 2026-02-26 |
| 2023-09-30 | $22.28M 10-Q · filed 2024-11-07 | $36.96M derived: sum of 2 quarters · filed 2024-11-07 | $16.21M 10-Q · filed 2024-11-07 | $12.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $14.68M 10-Q · filed 2024-08-08 | -$4.42M 10-Q · filed 2024-08-08 | -$9.94M derived: sum of 3 quarters · filed 2025-02-27 | -$9.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$17.43M 10-Q · filed 2024-05-09 | -$24.63M derived: sum of 2 quarters · filed 2025-02-27 | -$24.17M derived: sum of 3 quarters · filed 2025-02-27 | -$29.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$6.74M derived: sum of 2 quarters · filed 2025-02-27 | -$11.93M derived: sum of 3 quarters · filed 2025-02-27 | -$25.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | $457.00K 10-Q · filed 2023-11-07 | -$4.73M derived: sum of 2 quarters · filed 2023-11-07 | -$17.80M 10-Q · filed 2023-11-07 | -$41.67M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$5.19M 10-Q · filed 2023-08-03 | -$18.26M 10-Q · filed 2023-08-03 | -$42.12M derived: sum of 3 quarters · filed 2024-02-22 | -$34.08M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$13.07M 10-Q · filed 2023-05-04 | -$36.93M derived: sum of 2 quarters · filed 2024-02-22 | -$28.89M derived: sum of 3 quarters · filed 2024-02-22 | $45.13M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$23.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$15.82M derived: sum of 2 quarters · filed 2024-02-22 | $58.19M derived: sum of 3 quarters · filed 2024-02-22 | $76.19M 10-K · filed 2024-02-22 |
| 2021-09-30 | $8.05M 10-Q · filed 2022-11-03 | $82.06M derived: sum of 2 quarters · filed 2022-11-03 | $100.06M 10-Q · filed 2022-11-03 | $105.84M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $74.01M 10-Q · filed 2022-08-04 | $90.84M 10-Q · filed 2022-08-04 | $97.80M derived: sum of 3 quarters · filed 2023-02-23 | $109.08M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $16.83M 10-Q · filed 2022-05-10 | $23.79M derived: sum of 2 quarters · filed 2023-02-23 | $35.07M derived: sum of 3 quarters · filed 2023-02-23 | $43.13M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $18.24M derived: sum of 2 quarters · filed 2023-02-23 | $26.30M derived: sum of 3 quarters · filed 2023-02-23 | $26.75M 10-K · filed 2023-02-23 |
| 2020-09-30 | $11.29M 10-Q · filed 2021-11-04 | $19.34M derived: sum of 2 quarters · filed 2021-11-04 | $19.79M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $8.06M 10-Q · filed 2021-08-05 | $8.51M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $450.00K 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$22.72M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |